JSPRW
Jasper Therapeutics IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-3.84
Beta
3.08
52W High
$0.18
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Jasper Therapeutics Inc
Jasper Therapeutics Inc. is a clinical-stage biotechnology company dedicated to pioneering advanced therapies for serious diseases through its innovative hematopoietic cell transplantation platform. The company’s lead candidate, JSP191, demonstrates promising efficacy in treating blood disorders, showing potential for enhanced patient outcomes in early clinical trials. With a robust pipeline and an experienced leadership team, Jasper Therapeutics is well-positioned to drive significant advancements in cell therapy and regenerative medicine as it progresses through key clinical development phases.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.94M |
| Operating Margin | 0.00% |
| Return on Equity | -244.20% |
| Return on Assets | -112.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.12 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $21.88M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
229.65%
HV 20-Day
184.57%
HV 30-Day
163.67%
HV 60-Day
151.76%
HV Rank
—
Volatility is currently expanding
Data last updated: 5/25/2026